LOGIN  |  REGISTER
Astria Therapeutics
Terns Pharmaceuticals

Alphatec to Participate in Upcoming Investor Conferences

February 21, 2023 | Last Trade: US$16.18 0.13 0.81

CARLSBAD, Calif. / Feb 21, 2023 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor events:

  • The Cowen Healthcare Conference in Boston, MA, with a fireside chat at 2:10 pm ET on March 6, 2023
  • The Canaccord Genuity Musculoskeletal Conference in Las Vegas, NV, with a fireside chat at 2:30 pm PT on March 7, 2023
  • The Loop Capital Markets Annual Investor Conference (virtually) on March 13, 2023
  • The Barclays Healthcare Conference in Miami, FL, with a fireside chat at 2:05 pm ET on March 15, 2023

If available, webcasts of the conference presentations and archived recordings will be available in the Investor Relations Section of the Company’s website.

About ATEC

ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine™ is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page